
Endo International plc ENDP
Geschäftsbericht 2023
hinzugefügt 06.03.2024
Endo International plc Betriebsaufwand 2011-2026 | ENDP
Betriebsaufwand Jährlich Endo International plc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 763 M | 832 M | 802 M | 954 M | 844 M | 950 M | 992 M | 1.12 B | 1.04 B |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.12 B | 763 M | 922 M |
Betriebsaufwand anderer Aktien in der Arzneimittelhersteller
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M | ||
|
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
38.9 M | - | 0.86 % | $ 117 M | ||
|
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | ||
|
Canopy Growth Corporation
CGC
|
197 M | $ 1.1 | 3.77 % | $ 118 M | ||
|
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | ||
|
Evoke Pharma
EVOK
|
12.6 M | - | - | $ 36.6 M | ||
|
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M | ||
|
Cronos Group
CRON
|
154 M | $ 2.66 | 2.12 % | $ 1.35 B | ||
|
Evolus
EOLS
|
107 M | $ 5.46 | 32.2 % | $ 352 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
196 M | - | - | $ 2.06 B | ||
|
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | ||
|
China Pharma Holdings
CPHI
|
2.6 M | $ 0.57 | 3.55 % | $ 9.95 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 4.58 | - | $ 64.4 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
213 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M | ||
|
Neoleukin Therapeutics
NLTX
|
55.6 M | - | - | $ 193 M | ||
|
Aurora Cannabis
ACB
|
183 M | $ 3.65 | 4.89 % | $ 86.3 M | ||
|
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | ||
|
Harrow Health
HROW
|
174 M | $ 39.84 | 3.2 % | $ 1.46 B | ||
|
Emergent BioSolutions
EBS
|
558 M | $ 8.88 | -0.34 % | $ 455 M | ||
|
ProPhase Labs
PRPH
|
47.1 M | - | - | $ 5.07 M | ||
|
Assertio Holdings
ASRT
|
133 M | $ 11.86 | -0.29 % | $ 842 M | ||
|
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | ||
|
Bausch Health Companies
BHC
|
4.96 B | $ 5.63 | -1.66 % | $ 2.05 B | ||
|
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | ||
|
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | ||
|
Organogenesis Holdings
ORGO
|
368 M | $ 2.89 | 0.7 % | $ 381 M | ||
|
OrganiGram Holdings
OGI
|
41.4 M | $ 1.4 | 1.85 % | $ 402 M | ||
|
Rockwell Medical
RMTI
|
31.1 M | $ 0.89 | -1.05 % | $ 20.8 M | ||
|
Perrigo Company plc
PRGO
|
2.62 B | $ 11.57 | 1.62 % | $ 1.6 B | ||
|
Sundial Growers
SNDL
|
102 K | $ 1.55 | 0.98 % | $ 3.37 M | ||
|
Veru
VERU
|
44 M | $ 2.56 | 1.39 % | $ 345 M | ||
|
Viatris
VTRS
|
5.67 B | $ 14.89 | -0.03 % | $ 17.9 B | ||
|
cbdMD
YCBD
|
28.9 M | $ 0.76 | -2.68 % | $ 3.28 M | ||
|
TherapeuticsMD
TXMD
|
9.82 M | $ 2.3 | 3.57 % | $ 24 M | ||
|
Pacira BioSciences
PCRX
|
279 M | $ 22.11 | 0.05 % | $ 1.02 B | ||
|
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | ||
|
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | ||
|
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
104 M | $ 4.66 | -0.32 % | $ 140 M | ||
|
SCYNEXIS
SCYX
|
67.5 M | $ 0.75 | -0.27 % | $ 35.9 M | ||
|
Solid Biosciences
SLDB
|
130 M | $ 5.96 | 0.02 % | $ 243 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 2.75 | - | $ 3.41 M | ||
|
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
1.52 B | $ 7.53 | 2.31 % | $ 4.65 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
35.3 M | - | - | $ 55.5 M |